In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these ...

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney ...

For patients with obesity, clinicians should move beyond a "try and fail" approach to lifestyle interventions and prioritize ...

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

It's a critical time to spotlight the dire health disparities affecting Black Americans, from premature deaths to maternal ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...